Overview

IL2-inducible T-cell kinase (ITK) is a gene that encodes a protein that functions as an intracellular tyrosine kinase expressed in T-cells. The protein may also be important in T-cell proliferation and differentiation. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as intestinal cancer, pleural cancer, and skin cancer.

ITK is altered in 0.54% of all cancers with lung adenocarcinoma, melanoma, colon adenocarcinoma, glioblastoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in ITK are ITK R96C (0.07%), ITK R448H (0.06%), ITK R562Q (0.06%), ITK A471T (0.04%), and ITK R44H (0.04%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.